Altimmune, Inc. filings document a late clinical-stage biopharmaceutical issuer focused on pemvidutide for serious liver diseases, along with the capital structure used to support that development. Its Form 8-K reports cover operating-result announcements, underwriting agreements, registered direct and at-the-market equity programs, pre-funded warrants, common stock warrants and loan agreement amendments.
Altimmune’s proxy and annual meeting materials disclose shareholder voting matters, governance procedures, executive compensation information and amendments to its certificate of incorporation, including authorized-share matters. The filings also identify its common stock as listed on The Nasdaq Global Market under the symbol ALT.
Altimmune, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on September 25, 2025. As of the August 12, 2025 record date, 88,257,253 common shares were outstanding and entitled to vote. A total of 51,688,116 shares were present in person or by proxy, representing 58.6% of the voting power and establishing a quorum.
Stockholders elected all nominated directors, including Chairman Jerome Durso and Chief Executive Officer Vipin K. Garg, Ph.D., with each nominee receiving more votes “for” than “withheld.” Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2025, with 48,959,891 votes for, 1,355,769 against and 1,372,456 abstentions.
In an advisory “say-on-pay” vote, stockholders approved the compensation of Altimmune’s named executive officers, with 14,885,881 votes for, 6,683,682 against and 267,424 abstentions, plus 29,851,129 broker non-votes. Stockholders also approved a proposal to authorize possible adjournment of the meeting to allow additional proxy solicitation, with 33,695,815 votes for, 16,363,206 against and 1,629,095 abstentions.
Altimmune insider grant summary: Linda M. Richardson, listed as Chief Commercial Officer and a director, reported equity awards on 09/16/2025. She was awarded stock options to purchase 278,000 shares with an exercise price of $3.63 and restricted stock units representing 96,000 shares. Both awards vest over four years, with 25% vesting on September 16, 2026, and the remainder vesting in installments thereafter; the options expire September 16, 2035. Following the transaction, Richardson beneficially owns 278,000 option shares and 96,000 RSUs as reported. The filing was signed by an attorney-in-fact on 09/17/2025.
Altimmune, Inc. (ALT) Form 3: Linda M. Richardson submitted an initial Section 16 Form 3 reporting relationship to Altimmune as Chief Commercial Officer and a director-level officer. The filing states the date of the event as 09/16/2025 and the Form was signed by an attorney-in-fact on 09/17/2025. The Form explicitly notes no securities are beneficially owned by the reporting person and includes Exhibit 24 (Power of Attorney).
Altimmune, Inc. (ALT) is holding a virtual 2025 Annual Meeting of Stockholders on September 25, 2025 at 8:30 a.m. Eastern accessible at https://www.cstproxy.com/altimmune/2025 using a 12-digit control number. The proxy statement presents routine governance items: election of directors, ratification of Ernst & Young (E&Y) as independent auditors for the year ending December 31, 2025, an annual advisory "say-on-pay" vote on named executive officer compensation, and authorization to adjourn the meeting.
The filing references corporate governance materials and the Company Code of Ethics available on the investor relations site and notes the Audit Committee received PCAOB-required disclosures from E&Y and recommended inclusion of audited financial statements in the 2024 Form 10-K. Named executive officers listed for 2024 include Vipin K. Garg, Ph.D. (CEO), M. Scott Harris, M.D. (CMO), and M. Scot Roberts, Ph.D. (CSO). Benefit highlights include a 401(k) Plan with a 100% match on the first 4% of participant contributions. The statement also describes director nomination processes and related-party/merger background.
Altimmune reported strong clinical topline results from its IMPACT Phase 2b MASH trial, where weekly pemvidutide produced MASH resolution rates of 59.1% (1.2 mg) and 52.1% (1.8 mg) versus 19.1% for placebo (p<0.0001 for both doses). Fibrosis improvement by conventional ITT analysis was not statistically different, but an AI-based analysis showed a larger fibrosis reduction signal (30.6% of subjects on 1.8 mg achieved ≥60% fibrosis reduction versus 8.2% on placebo, p<0.001). Pemvidutide also drove mean weight loss of 5.0% and 6.2% at 1.2 mg and 1.8 mg versus 1.0% for placebo, and safety/tolerability appeared favorable with low discontinuation rates.
On the balance sheet, cash and equivalents were $183.1M at June 30, 2025, the company drew $15.0M of a $100M term loan facility (effective interest rate 14.4%), and generated net proceeds of $72.6M from at-the-market equity offerings in the period plus an additional $12.8M raised in July. The company recorded a six-month net loss of $41.7M and has an accumulated deficit of $603.1M. A class action alleging securities law violations was filed on August 5, 2025.
Altimmune, Inc. filed a current report to furnish a press release announcing its financial results for the second quarter ended June 30, 2025. The press release, dated August 12, 2025, is included as Exhibit 99.1 and is provided for informational purposes rather than being formally filed under securities laws.
Altimmune (Nasdaq: ALT) filed an 8-K reporting positive topline data from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
- MASH resolution without fibrosis worsening reached 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001).
- Histologic fibrosis improvement (31.8%/34.5% vs 25.9% placebo) was not significant, but AI analysis showed ≥60% fibrosis reduction in 30.6% at 1.8 mg vs 8.2% placebo (p<0.001).
- Mean weight loss 5.0%/6.2% vs 1.0% placebo (p<0.001); liver fat fell 58.0%/62.8% vs 16.2%.
- Safety: 0–1.2% AE-related discontinuations; no drug-related SAEs.
Slides (Ex 99.2) accompany a call on 26 Jun 2025. Forward-looking statements cite regulatory, trial and funding risks.